Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cellectis SA ( (CLLS) ) has issued an update.
Cellectis S.A. announced that Pierre Bastid will resign from the Board of Directors following the Combined General Meeting of Shareholders on June 26, 2025. His resignation is not due to any disagreements with the company. The meeting will address several agenda items, including the approval of financial statements for 2024, board appointments, and various authorizations related to share capital adjustments. These decisions are pivotal for Cellectis as they aim to strengthen their financial structure and governance, potentially impacting their market position and stakeholder relations.
The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA shows potential with strong strategic partnerships and financial positioning through collaboration with AstraZeneca. However, profitability challenges and negative valuation metrics weigh down the score. Positive momentum in technical analysis and a strong earnings call provide some upside.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a biotechnology company based in Paris, France, specializing in the development of gene-editing technologies. The company focuses on creating innovative solutions for the healthcare sector, particularly in the field of oncology and immunotherapy.
Average Trading Volume: 331,128
Technical Sentiment Signal: Sell
Current Market Cap: $109.8M
See more data about CLLS stock on TipRanks’ Stock Analysis page.